Amgen’s obesity drug puts stock on pace for best day since 2009 as analysts predict big gains to come

One analyst says Amgen’s stock is in the ”early innings of a large move,” fueled by an experimental obesity drug.

Previous post ISM service-sector gauge weakens sharply in April
Next post Goldman Sachs settles lawsuit that alleged violations in platinum and palladium trading